Talent
Investor Portal
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Newsroom
latest news from ose
and across our portfolio
Featured News
October 19, 2022
DJS Antibodies to be acquired by AbbVie
August 3, 2022
MiroBio to be acquired by Gilead Sciences for approximately $405 million
July 17, 2022
Oxford Science Enterprises raises £250 million
Article links to firstlightfusion.com
April 4, 2022
First Light Fusion achieves world first fusion result, proving unique new target technology
Article links to www.omass.com
April 27, 2022
OMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseases
Article links to www.oslerdiagnostics.com
November 7, 2022
Osler Diagnostics raises $85 million in Series C financing
Article links to quantummotion.tech
October 25, 2022
Quantum Motion industry milestone brings mass production of quantum chips closer
December 13, 2022
OxfordVR to combine with BehaVR to confront the mental health crisis with the largest VR delivery platform for evidence-based digital therapeutics
All News
02•02•23
Portfolio News
Orbit Discovery
Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics
01•02•23
Portfolio News
Scenic Biotech
Scenic Biotech enters cooperative research and development agreement with the National Institutes of Health for genetic modifier-based treatment approach for Niemann-Pick Type C Disease
31•01•23
Portfolio News
Vaccitech
Vaccitech appoints industry veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
26•01•23
Portfolio News
Grey Wolf Therapeutics
Grey Wolf Therapeutics closes oversubscribed $49 million Series B financing to advance first-of-its-kind neoantigen creation approaches
26•01•23
Portfolio News
First Light Fusion
First Light Fusion to build demonstration facility at UKAEA’s Culham Campus
24•01•23
Portfolio News
Amber Therapeutics
Amber Therapeutics announces successful first-in-human implants of Amber-UI: an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinence
20•01•23
Portfolio News
Scenic Biotech
Scenic Biotech strengthens drug discovery expertise in management team with the addition of Kristof Van Emelen
09•01•23
Portfolio News
Oxford Ionics
Oxford Ionics announces £30m series A funding
06•01•23
Portfolio News
Perspectum
Perspectum completes $36 million first close of series C funding led by Oppenheimer Holding
05•01•23
Portfolio News
Argonaut Therapeutics and Celleron Therapeutics announce completion of merger to form IngenOx Therapeutics
05•01•23
Portfolio News
Orbit Discovery
Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs
13•12•22
Portfolio News
First Light Fusion
First Light Fusion congratulates the National Ignition Facility on its maiden gain result
13•12•22
OSE News
BehaVR
OxfordVR to combine with BehaVR to confront the mental health crisis with the largest VR delivery platform for evidence-based digital therapeutics
12•12•22
Portfolio News
First Light Fusion
First Light welcomes news of possible 'Net Energy Gain' success at The National Ignition Facility
07•12•22
Portfolio News
PepGen
PepGen announces IND-enabling preclinical data supporting progression of PGN-EDODM1 into clinical studies
06•12•22
Portfolio News
Ultromics
Ultromics receives FDA clearance for its breakthrough device EchoGo Heart Failure
29•11•22
Portfolio News
Navenio
Bill Kloes joins Navenio as Chief Operating Officer to drive US expansion
28•11•22
Portfolio News
First Light Fusion
First Light Fusion targets 60 MW pilot plant to accelerate tritium production
21•11•22
Portfolio News
Vaccitech
Vaccitech to host KOL webinar on the SNAPvax™ platform for inducing tolerance to treat celiac and other autoimmune diseases
16•11•22
Portfolio News
Orca Computing
ORCA Computing hires Per Nyberg as Chief Commercial Officer
14•11•22
Portfolio News
PepGen
PepGen announces positive preclinical data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, three novel duchenne muscular dystrophy candidates
10•11•22
Portfolio News
Vaccitech
Vaccitech reports third quarter 2022 financial results and recent corporate developments
10•11•22
Portfolio News
OMass Therapeutics
Publication in Nature Chemistry between Omass Therapeutics and co-founder Dame Carol Robinson demonstrates the benefits of native mass spectrometry in the interrogation of target ecosystems and drug discovery
10•11•22
Portfolio News
PepGen
PepGen reports third quarter 2022 financial results and recent corporate developments
07•11•22
Portfolio News
Genomics
Genomics announces successful world-first pilot using improved genomic risk assessment in cardiovascular disease prevention in the NHS
07•11•22
Portfolio News
Osler Diagnostics
Osler Diagnostics raises $85 million in Series C financing
03•11•22
Portfolio News
Util
Util closes $6 million seed investment round led by Eldridge
01•11•22
Portfolio News
Evolito
Evolito appoints Chris Harris as Chief Executive Officer
25•10•22
Portfolio News
Quantum Motion Technologies
Quantum Motion industry milestone brings mass production of quantum chips closer
23•10•22
Portfolio News
Scenic Biotech
Scenic Biotech appoints Jens Würthner as Chief Medical Officer
19•10•22
OSE News
DJS Antibodies
DJS Antibodies to be acquired by AbbVie
19•10•22
Portfolio News
DJS Antibodies
AbbVie acquires DJS Antibodies, further strengthening immunology pipeline
18•10•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines
12•10•22
Portfolio News
PepGen
PepGen presents data from its Duchenne Muscular Dystrophy program at World Muscle Society Congress
11•10•22
OSE News
Oxford University named world's top university for the 7th consecutive year
09•10•22
Portfolio News
Genomics
Genomics announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches
05•10•22
Portfolio News
Theolytics
Theolytics presents CAF-targeting therapy for stromal rich tumours and strengthens leadership team
28•09•22
Portfolio News
Ultromics
Ultromics joins FNIH partnership to transform heart failure detection
27•09•22
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits partners with Cyxtera to improve accessibility to quantum computers
27•09•22
Portfolio News
PepGen
PepGen reports positive data from Phase 1 trial of PGN-ED051 for the treatment of Duchenne Muscular Dystrophy
25•09•22
Portfolio News
First Light Fusion
Government Chief Scientific Adviser visits UK Atomic Energy Authority and First Light Fusion
25•09•22
Portfolio News
PepGen
PepGen appoints Habib Dable to Board of Directors
13•09•22
Portfolio News
Odqa
Odqa Renewable Energy Technologies emerges as frontrunner in the solar thermal industry with proprietary receiver technology
07•09•22
Portfolio News
Opsydia
Opsydia secures investment to drive growth in its innovative security solutions for the diamond sector
06•09•22
Portfolio News
Genomics
Genomics announces that Simon Dingemans has joined its board as the new chair
20•08•22
Portfolio News
Refeyn
Refeyn appoints Jean-Paul Mangeolle as new Non-Executive Director
11•08•22
Portfolio News
PepGen
PepGen reports second quarter 2022 financial results and recent corporate developments
08•08•22
Portfolio News
Vaccitech
Vaccitech reports second quarter 2022 financial results and recent corporate developments
03•08•22
Portfolio News
MiroBio
Gilead Sciences to acquire MiroBio
03•08•22
OSE News
MiroBio
MiroBio to be acquired by Gilead Sciences for approximately $405 million
21•07•22
Portfolio News
PepGen
PepGen appoints Caroline Godfrey, Ph.D. to the company's scientific advisory board
20•07•22
Portfolio News
First Light Fusion
First Light Fusion strikes long-term collaboration agreement with engineering leaders IDOM
19•07•22
Portfolio News
Brill Power
Brill powering its way to make batteries smarter with $10.5m Series A round
17•07•22
OSE News
Oxford Science Enterprises raises £250 million
14•07•22
Portfolio News
OMass Therapeutics
OMass Therapeutics appoints Dr Jon Roffey as Vice President, Head of Medicinal Chemistry
11•07•22
Portfolio News
SpyBiotech
SpyBiotech appoints seasoned biotech executive Mark Leuchtenberger as Chief Executive Officer
05•07•22
Portfolio News
Oxford Ionics
Oxford Ionics and Infineon join forces to develop leading trapped ion quantum processors
04•07•22
Portfolio News
Evolito
Evolito acquires Electroflight
04•07•22
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits raises £38 million Series A to accelerate R&D and expand into Asia-Pacific
04•07•22
Portfolio News
PQShield
PQShield algorithms to be standardised as the National Institute of Standards and Technology (NIST) announces the first international Post-Quantum Cryptography standards
28•06•22
Portfolio News
MiroBio
MiroBio raises $97 million Series B financing to develop checkpoint agonists for treatment of autoimmune diseases
21•06•22
Portfolio News
Vaccitech
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
15•06•22
Portfolio News
PepGen
PepGen reports first quarter 2022 financial results and recent corporate developments
13•06•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Dina Anderson as Vice President of Operations
09•06•22
Portfolio News
Orca Computing
Orca Computing provides UK MoD with first quantum computer
08•06•22
Portfolio News
Bibliu
EdTech leader BibliU raises $15 million in Series B funding
08•06•22
Portfolio News
Orca Computing
Orca Computing completes $15 million Series A funding round
05•06•22
Portfolio News
Vaccitech
Arbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virus
31•05•22
Portfolio News
Theolytics
Theolytics' £1m project with Innovate UK to develop a novel therapy for multiple myeloma patients
30•05•22
Portfolio News
MoA Technology
MoA Technology raises $44 million in Series B financing to progress novel herbicide pipeline
21•05•22
Portfolio News
Perspectum
FDA grants clearance to Perspectum's CoverScan - A new platform-based tool to assess multiple organs in one MRI scan
11•05•22
Portfolio News
Salience Labs
Salience Labs raises $11.5 million seed to develop ultra high-speed chips using photonics for AI applications
04•05•22
Portfolio News
PepGen
PepGen announces pricing of initial public offering
28•04•22
Portfolio News
SpyBiotech
Studies using SpyBiotech’s vaccine technology shows potential against Covid-19 and other coronaviruses
27•04•22
Portfolio News
OMass Therapeutics
OMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseases
20•04•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Phil Boyd as Chief Financial Officer
18•04•22
OSE News
Oxford Science Enterprises appoints Richard Laxer, former Chairman and CEO of GE Capital, as a Non-Executive Director
12•04•22
Portfolio News
Util
Util announces the closing of a seed round
10•04•22
Portfolio News
Refeyn
Refeyn closes Series B funding round
06•04•22
Portfolio News
BehaVR
OxfordVR technology a world-first success in automating psychological therapy using virtual reality
06•04•22
Portfolio News
Vaccitech
Vaccitech announces notification of milestone and royalty revenue relating to sales of Vaxzevria
05•04•22
Portfolio News
OMass Therapeutics
Publication in Nature by OMass Founder, Professor Dame Carol Robinson, shows power of native mass spectrometry in drug discovery
05•04•22
Portfolio News
PepGen
PepGen announces first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy
04•04•22
Portfolio News
First Light Fusion
First Light Fusion achieves world first fusion result, proving unique new target technology
04•04•22
Portfolio News
PepGen
PepGen appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development
03•04•22
OSE News
New report highlights Oxford as the UK’s leading University for spinout creation with Oxford Science Enterprises named as most active fund focused solely on a single institution
30•03•22
OSE News
Oxford Science Enterprises strengthens investment teams with two new appointments
29•03•22
Portfolio News
PepGen
PepGen continues to build leadership team with additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
29•03•22
Portfolio News
Scenic Biotech
Scenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find tailored treatment for complex rare disease
25•03•22
Portfolio News
Vaccitech
Vaccitech reports full-year 2021 financial results and recent corporate developments
22•03•22
Portfolio News
Bibliu
Higher education tech leader BibliU announces learning enablement platform
22•03•22
Portfolio News
Mixergy
Mixergy partners with UK’s largest online plumbing and heating merchant to offer full range of tanks nationwide
21•03•22
Portfolio News
Osler Diagnostics
Osler Diagnostics publishes update on its breakthrough product, the Osler Origin
21•03•22
Portfolio News
Osler Diagnostics
Osler Diagnostics appoints Chris Smith as Chairman of the Board and David Berry as a Non-Executive Director
16•03•22
Portfolio News
Mind Foundry
Mind Foundry win CogX Explainable AI Award for 2022
15•03•22
Portfolio News
PepGen
PepGen announces approval by Health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular Dystrophy
14•03•22
OSE News
Oxford Science Enterprises enters agreement with Lothbury to develop state-of-the-art R&D facilities in Oxford City Centre
10•03•22
Portfolio News
Scenic Biotech
Scenic Biotech announces $31 million financing to progress pipeline of genetic modifiers in cancer and rare diseases
08•03•22
Portfolio News
MiroBio
MiroBio continues expansion of executive leadership team with key appointments to advance development of checkpoint agonist antibodies for autoimmune disease
07•03•22
Portfolio News
OMass Therapeutics
OMass Therapeutics establishes scientific advisory board of leading experts
07•03•22
Portfolio News
Orbit Discovery
Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies
04•03•22
Portfolio News
OMass Therapeutics
Omass Therapeutics OdyssION™ drug discovery platform makes progress in drugging the undruggable
01•03•22
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits becomes first european quantum company on Amazon Braket
15•02•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics appoints Nigel Clark as Chief Business Officer
15•02•22
Portfolio News
Ultromics
Ultromics: Wolverhampton NHS cardiologists to use new cloud technology to interpret echocardiograms
14•02•22
Portfolio News
First Light Fusion
First Light Fusion announces close of Series C fund raise
11•02•22
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics announces formation of advisory board
11•02•22
OSE News
Oxford Science Enterprises strengthens investment teams with two senior appointments
09•02•22
Portfolio News
Metaboards
Metaboards announces Executive Chairman appointment
09•02•22
Portfolio News
Refeyn
Refeyn announces the launch of its new TwoMP Auto mass photometer
07•02•22
Portfolio News
Opsydia
Opsydia introduces Surface ID System to complement existing sub-surface technology
07•02•22
Portfolio News
Quantum Motion Technologies
Quantum Motion opens new lab in London to build scalable quantum computer
27•01•22
Portfolio News
Perspectum
Perspectum announces first patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric study
26•01•22
Portfolio News
PQShield
PQShield raises $20 million in Series A funding to fuel global growth
25•01•22
OSE News
Oxford Science Enterprises enters 2022 with strengthened senior leadership team
20•01•22
Portfolio News
Brill Power
Brill Power announces Harwell Campus to provide testbed demonstrating energy storage innovations
20•01•22
Portfolio News
Oxford Nanoimaging
Oxford Nanoimaging closes $75 million Series B led by ARCH Venture Partners and Casdin Capital
18•01•22
Portfolio News
Vaccitech
Vaccitech announces Cancer Research UK dose first patient in Phase I/IIa trial of lung cancer immunotherapy vaccine
16•12•21
Portfolio News
Navenio
Navenio secures $12.6 million investment to accelerate global growth in healthcare and beyond
16•12•21
OSE News
Oxford Science Enterprises Board update
15•12•21
Portfolio News
Ultromics
Ultromics breakthrough study shows AI is a capable of independently reading stress echocardiograms
15•12•21
Portfolio News
Alethiomics
Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer
14•12•21
Portfolio News
Circadian Therapeutics
Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marking move to a clinical stage company
13•12•21
Portfolio News
Vaccitech
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
07•12•21
Portfolio News
Vaccitech
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
06•12•21
Portfolio News
Oxford Semantic Technologies
Dow Jones enhances product line with semantic innovation from Oxford Semantic Technologies
29•11•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits coming to Amazon Braket - bringing quantum to Europe
22•11•21
Portfolio News
Meltwater acquires AI spin-out from Oxford University’s Department of Computer Science to help build one of the largest knowledge graphs of public information
18•11•21
Portfolio News
Mixergy
Ecobubl: A new Mixergy stockist and training centre
16•11•21
Portfolio News
Oxford Flow
Valve industry veteran, Colin Findley, joins Oxford Flow as Chief Strategy Officer
16•11•21
Portfolio News
SpyBiotech
SpyBiotech announces the appointment of Simon Jones as VP, Finance and Operations and expansion of the scientific team
12•11•21
Portfolio News
Vaccitech
Vaccitech reports third quarter 2021 financial results and recent corporate developments
12•11•21
Portfolio News
Vaccitech
Vaccitech’s VTP-300 was well-tolerated and induced T cells against all targeted HBV antigens in both healthy volunteers and patients with chronic HBV infection in interim analyses
09•11•21
Portfolio News
Ultromics
Caption Health and Ultromics partner to put heart disease detection and management tools in more hands
08•11•21
Portfolio News
Caristo Diagnostics
Caristo Diagnostics announces CT coronary perivascular fat assessment can stratify cardiac risk associated with high-risk plaques
08•11•21
Portfolio News
Evox Therapeutics
Evox Therapeutics expands its exosome patent portfolio
08•11•21
Portfolio News
PepGen
PepGen bolsters R&D team with appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development
05•11•21
Portfolio News
Navenio
Navenio and HERE Technologies to bring increased efficiency to indoor location & mapping with global partnership
05•11•21
Portfolio News
Nucleome Therapeutics
Gene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome Therapeutics
04•11•21
Portfolio News
OMass Therapeutics
OMass Therapeutics unveils rich drug discovery pipeline targeting intractable or inadequately drugged membrane and complex-bound proteins
04•11•21
Portfolio News
Vaccitech
Vaccitech announces publication of second Phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirus
03•11•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits collaborates with the National Quantum Computing Centre to boost UK quantum capability
01•11•21
Portfolio News
Bibliu
Wichita State University Campus of Applied Sciences and Technology adopts BibliU Universal Learning
01•11•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits pledges carbon neutrality by 2022
27•10•21
Portfolio News
PepGen
PepGen appoints Noel Donnelly as Chief Financial Officer
21•10•21
Portfolio News
Evox Therapeutics
Landmark paper highlights Evox Therapeutics’ cutting edge exosome engineering approach for enhanced surface display of biologics
06•10•21
Portfolio News
First Light Fusion
First Light Fusion represents UK fusion sector at the UK Government’s Global Investment Summit
05•10•21
Portfolio News
Brill Power
Brill Power launches the first in a new class of 'intelligent' battery management systems set to revolutionise battery performance
01•10•21
Portfolio News
Ultromics
Ultromics announces collaboration with Janssen to develop AI for patients with amyloidosis with cardiac involvement
30•09•21
Portfolio News
Opsydia
Opsydia technology advances to secure identity of melee diamonds
30•09•21
Portfolio News
PQShield
PQShield announces new hires to accelerate business growth
23•09•21
Portfolio News
Evolito
YASA spin-out Evolito to electrify aerospace market with ultra-high performance, low-weight electric motors
12•09•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits appoints Peter George as Chairperson of its Board
08•09•21
Portfolio News
PepGen
PepGen announces new additions to leadership team and Board of Directors
01•09•21
OSE News
Oxford University retains top spot in world rankings for 6th consecutive year
23•08•21
Portfolio News
Genomics
Genomics academic founder and CEO, Sir Peter Donnelly, awarded Royal Society Gabor medal
15•08•21
Portfolio News
Ultromics
Ultromics raises $33 million in Series B funding to help transform cardiac disease treatment
04•08•21
Portfolio News
PepGen
PepGen announces closing of $112.5 million crossover financing to advance transformative therapies for neuromuscular diseases
21•07•21
Portfolio News
Circadian Therapeutics
Circadian Therapeutics and Arquimea sign a collaboration agreement for the development of a molecule (AP-2) for the treatment of diseases affecting the nervous system
21•07•21
Portfolio News
YASA
Electric motor technology company YASA acquired by Mercedes-Benz
20•07•21
Portfolio News
Orbit Discovery
Orbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery business
08•07•21
Portfolio News
Perspectum
Perspectum launches new clinical study to investigate integrated diagnostics to enable precision medicine for liver cancer patients
07•07•21
Portfolio News
Theolytics
Theolytics expands Series A financing and welcomes M Ventures as a new investor
06•07•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits delivers the UK’s first Quantum Computing as-a-Service
06•07•21
Portfolio News
Vaccitech
Arbutus Biopharma and Vaccitech announce clinical trial collaboration for chronic hepatitis B virus infection
17•06•21
Portfolio News
Ultromics
Ultromics: EchoGo predicts cardiac-related COVID-19 mortality revealed in WASE study
16•06•21
Portfolio News
First Light Fusion
UK Science Minister Amanda Solloway MP to launch First Light Fusion’s maiden ‘Big Gun’ fusion campaign
14•06•21
Portfolio News
Brill Power
DNV verifies Brill Power’s new battery management system technology
07•06•21
Portfolio News
Oxford Nanoimaging
Oxford Nanoimaging among the +20 organisations brought together by the Cell and Gene Therapy Catapult to accelerate technology development in cell and gene therapy manufacturing
06•06•21
Portfolio News
PepGen
PepGen strengthens leadership team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments
24•05•21
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
24•05•21
Portfolio News
Nucleome Therapeutics
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
17•05•21
Portfolio News
Oxford Nanoimaging
Oxford Nanoimaging welcomes Dr Tyler Ralston as Chief Technology Officer
12•05•21
Portfolio News
First Light Fusion
First Light Fusion installs UK’s biggest two-stage hyper-velocity gas gun
03•05•21
Portfolio News
Perspectum
Perspectum partners in a new study in Singapore for the early detection of liver cancer using precision medicine
03•05•21
Portfolio News
Vaccitech
Vaccitech announces closing of $110.5 million initial public offering
28•04•21
Portfolio News
Vaccitech
Vaccitech announces pricing of initial public offering
26•04•21
Portfolio News
MoA Technology
MoA Technology raises a further £5 million in Series A financing bringing the total round to £12m
25•04•21
Portfolio News
Perspectum
Perspectum study shows measurable organ impairment in long COVID patients
19•04•21
Portfolio News
Ultromics
Ultromics CE mark's EchoGo Core
08•04•21
Portfolio News
Oxford Endovascular
Oxford Endovascular raises $10 million to develop its origami engineered medical device to prevent brain haemorrhage
30•03•21
Portfolio News
Quantum Motion Technologies
Quantum Motion computing breakthrough shows blueprint for scalable future
28•03•21
Portfolio News
Caristo Diagnostics
Caristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advance
28•03•21
Portfolio News
Perspectum
Perspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesity
22•03•21
Portfolio News
Vaccitech
Vaccitech appoints Joseph Scheeren, PharmD, to its Board of Directors
18•03•21
Portfolio News
Vaccitech
Vaccitech doses first patient in HPV001, a Phase 1/2 clinical trial of VTP-200 immunotherapeutic for high-risk persistent HPV infection
17•03•21
Portfolio News
Vaccitech
Vaccitech completes $168 million Series B financing to advance three clinical programs through Phase 2 results
08•03•21
Portfolio News
SpyBiotech
SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor
05•03•21
Portfolio News
MoA Technology
MoA Technology appoints Virginia Corless as Chief Executive Officer
02•03•21
Portfolio News
Vaccitech
Vaccitech appoints two independent board directors
01•03•21
Portfolio News
Genomics
Genomics completes oversubscribed $30m funding round
01•03•21
Portfolio News
Perspectum
Perspectum lands top spot in Alantra Pharma Fast 50 rankings
26•02•21
Portfolio News
PepGen
PepGen announces formation of scientific advisory board
25•02•21
Portfolio News
T-Cypher Bio
T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indications
18•02•21
Portfolio News
Evox Therapeutics
Evox Therapeutics completes £69.2 million Series C financing
17•02•21
Portfolio News
Brill Power
£2.5 million for intelligent battery technology start-up, Brill Power
16•02•21
Portfolio News
Mixergy
Mixergy tanks now included at CALA Homes development
10•02•21
Portfolio News
SpyBiotech
SpyBiotech raises $32.5 million in Series A funding and appoints Lutz B. Giebel as Chairman
04•02•21
Portfolio News
First Light Fusion
Professor Jerry Chittenden joins First Light Fusion’s Advisory Board
04•02•21
Portfolio News
PepGen
PepGen appoints James McArthur, Ph.D., as President and Chief Executive Officer
02•02•21
Portfolio News
Scenic Biotech
Scenic Biotech appoints Dr. Philippe Dro as Independent Chairman
01•02•21
Portfolio News
Vaccitech
Vaccitech doses first patient in HBV002, a Phase 1b/2a clinical trial of VTP-300 immunotherapeutic candidate for chronic HBV patients
18•01•21
Portfolio News
Evox Therapeutics
John McHutchison joins the board of Evox Therapeutics
15•01•21
Portfolio News
Perspectum
Perspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the body
08•01•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits lab takes delivery of first Proteox worldwide
08•01•21
Portfolio News
Oxford Quantum Circuits
Oxford Quantum Circuits state-of-the-art quantum laboratory opens
07•01•21
Portfolio News
Oxford Flow
Ex-Centrica and BP boss Iain Conn joins the board of Oxford Flow
06•01•21
Portfolio News
Ultromics
Ultromics receives FDA clearance for EchoGo Pro; a first-of-kind solution to help diagnose CAD
06•01•21
Portfolio News
Theolytics
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
05•01•21
Portfolio News
Perspectum
Perspectum issued CPT Codes for LiverMultiScan by the American Medical Association to help clinicians diagnose and treat liver disease
09•12•20
Portfolio News
HEXR
HEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millions
09•12•20
Portfolio News
PepGen
PepGen raises $45M in Series A funding, led by RA Capital
01•12•20
Portfolio News
PrOXisense
Counterfeit drugs and illegitimate vaccines, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford University
25•11•20
Portfolio News
Refeyn
Refeyn closes Series A funding round, led by Northpond Ventures
23•11•20
OSE News
Vaccitech
Breakthrough for Oxford's covid vaccine, co-invented by Vaccitech
19•11•20
Portfolio News
Evox Therapeutics
Evox Therapeutics announces launch of strategic collaboration with the University of Oxford
09•11•20
Portfolio News
Mind Foundry
Mind Foundry raises an additional $13.6 million in Series A funding
27•10•20
OSE News
Base Genomics
Oxford Science Enterprises announces the sale of Base Genomics to Exact Sciences
19•10•20
Portfolio News
Vaccitech
Vaccitech expands management team with new hires, including CMO and CFO
12•10•20
OSE News
Oxford Science Enterprises appoints Alexis Dormandy as Chief Executive Officer
11•10•20
Portfolio News
First Light Fusion
First Light Fusion: Fusion energy can be the most cost competitive source of baseload power, at the same level as renewables
20•09•20
Portfolio News
Scenic Biotech
Scenic Biotech enters into genetic modifier collaboration with Genentech
29•04•20
Portfolio News
Vaccitech
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Menu
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Talent
Investor Portal